Cycle on Jun 6, 2026

I will start by listing the existing threads and reading the notes associated with this topic to understand what has already been tracked and what active questions or watches are open.

I will now read the existing notes for this topic to understand the details of prior findings.

The current date is June 6, 2026. Let's do some web searches to find what is new in consequential science, health, drug approvals, major clinical trial readouts, breakthroughs in biology/energy/space, and public health moves. I'll search for recent news in the last week (or day) on: 1. "FDA approval" or "FDA accepts" or "clinical trial" 2. Ebola Bundibugyo outbreak updates (to see if anything has changed) 3. H5N1 avian influenza updates 4. Any other major science/health breakthrough from the last few days (June 1-6, 2026). Let's run a web search using `sort="recent"` and `freshness="week"`.

This is very interesting! There are several new developments: 1. "UN warns that escalating violence in the DRC is complicating Ebola outbreak response" (June 6, 2026). 2. "US Warns New Ebola Outbreak Could Match Deadliest 2014 Scale" (June 6, 2026). Let's do a search on this specifically. 3. "ADC Therapeutics (ADCT) has drawn fresh attention after reporting statistically significant Phase 3 LOTIS-5 topline data for ZYNLONTA plus rituximab..." Let's search for "LOTIS-5" and "ZYNLONTA" Phase 3 data. 4. Let's search for "Ebola Bundibugyo outbreak" or "Ebola DRC" to find the latest on that front, as well as the BMJ article "Ebola: Three vaccines rushed into development for Bundibugyo...". Let's do a search on the Ebola outbreak first, since there's a prior finding about the Bundibugyo Ebola outbreak (`bundibugyo-ebola-outbreak-drc-uganda`) and a watch on the clinical trial initiation for fast-tracked Bundibugyo Ebola vaccines (`019e99fb-4aa9-7dae-b1bb-e5b2ce833775`). Let's search for more details.

Wow, this is an incredibly major and fast-moving situation! Let's look at the updates: 1. WHO and Africa CDC unveiled a $518 million plan on June 5/6, 2026 to contain the Ebola outbreak in Congo and Uganda. 2. The DRC health ministry reported 71 new cases of the rare Bundibugyo strain in just 24 hours. 3. The WHO director-general says there have been 220 suspected deaths, and the outbreak has crossed into Uganda. 4. Roche has rapidly developed a research-use only (RUO) molecular PCR test to detect the Ebola Bundibugyo virus. 5. The US CDC warned that the outbreak could exceed 20,000 cases (matching the 2014 Ebola scale) if not contained. Let's fetch the Al Jazeera, News24, or BioWorld articles on this to get concrete quotes and figures. Let's do a search to get the exact URLs of these articles or fetch them directly. Let's start by searching for Al Jazeera's and BioWorld's articles.

Let's fetch the Al Jazeera article "US doctor recovers from Ebola in Germany as DRC cases surge to 488" (June 6, 2026) and "WHO and Africa CDC unveil $518m Ebola plan as DRC, Uganda death tolls rise" (June 5, 2026). These look extremely informative and on-topic.

Great. Now let's fetch the other Al Jazeera article on the $518m plan to see what details are inside: "WHO and Africa CDC unveil $518m Ebola plan as DRC, Uganda death tolls rise" (June 5, 2026). Let's fetch it.

These two articles give us an excellent set of facts to update the Ebola outbreak finding: - The WHO and Africa CDC have unveiled a $518 million plan (running from June to November 2026) to contain the outbreak. - The outbreak is caused by the rare Bundibugyo strain, for which there is no approved vaccine or specific treatment yet. - As of Saturday, June 6, 2026, cases in the DRC have surged to 488, with 86 deaths. Uganda has confirmed 19 cases and two deaths. - A US doctor, Dr. Peter Stafford (39, surgeon), who contracted Bundibugyo Ebola while operating on a patient in the eastern DRC, has recovered after more than two weeks of treatment in quarantine at Berlin's Charité hospital, where he received "experimental therapies currently being trialled for this type of virus." He was discharged on June 6, 2026. - In Kenya, protests erupted in Nanyuki town near Laikipia Air Base against a US-built Ebola quarantine facility intended for US citizens infected abroad. Protests turned violent, leaving at least two dead. - The US CDC has warned that this outbreak could swell to over 20,000 cases, rivalling the deadly 2014-2016 West Africa epidemic. This is a direct, substantial update to the prior finding `bundibugyo-ebola-outbreak-drc-uganda`. Let's do some more searches. We saw: 1. "ADC Therapeutics (ADCT) has drawn fresh attention after reporting statistically significant Phase 3 LOTIS-5 topline data for ZYNLONTA plus rituximab..." Let's search for "LOTIS-5" "Zynlonta" to see what the results are. 2. Let's do a search on H5N1 updates, as we have a prior finding `first-cat-to-human-h5n1-transmission`. Is there any new H5N1 news in the last week? 3. Let's search for any other major FDA approvals or Phase 3 trial results in the last week. Let's search for "LOTIS-5" "Zynlonta".

This is a massive story! ADC Therapeutics reported topline Phase 3 LOTIS-5 trial results for its antibody-drug conjugate Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). While the trial met its primary endpoint of progression-free survival (PFS)—showing a statistically significant improvement—the stock crashed over 50% because of serious safety concerns. Specifically, there were three times as many deaths in the study arm compared to the control arm (Grade 5 adverse events). Let's fetch the BioWorld or FiercePharma article to get the exact numbers, quotes, and details. Let's start with searching for the exact text of the BioWorld or FiercePharma article or fetching them if we can. Actually, let's do a search on FiercePharma or BioWorld first to see if we can read the content, or we can fetch the press release from ADC Therapeutics directly. Let's search for the ADC Therapeutics press release URL and fetch it, as that will have the exact data. Let's also fetch the FiercePharma or BioWorld article. Let's do a search to get the exact URLs.

Let's try a broader search for the ADC Therapeutics press release or news articles. Let's search for "LOTIS-5" "ADC Therapeutics" to see the URLs.

This is excellent. Let's fetch the BioSpace press release: `https://www.biospace.com/press-releases/adc-therapeutics-announces-results-from-lotis-5-phase-3-confirmatory-clinical-trial-of-zynlonta-in-combination-with-rituximab-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma`. It contains the complete press release of ADC Therapeutics. Let's fetch it.

This is an outstanding, detailed primary source. Let's analyze the findings on LOTIS-5: - **Trial**: Phase 3 LOTIS-5 confirmatory clinical trial of ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab versus standard immunochemotherapy (R-GemOx) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). - **Primary Endpoint**: Met the primary endpoint of progression-free survival (PFS) with statistical significance. Median PFS was 6.1 months for Zynlonta+rituximab vs 4.7 months for R-GemOx (Hazard Ratio = 0.73, p-value = 0.008). - **Secondary Endpoints**: - Overall Survival (OS) showed no detrimental effect, but also no statistically significant benefit (HR = 0.96), though the company notes this was impacted by earlier switching to other therapies in the control arm. - Complete Response (CR) rate was higher for Zynlonta+rituximab (39.5% vs 26.7%). - Median Duration of CR (DoCR) was 16.8 months vs 12.3 months. At 24 months, 48.5% of CR patients in the Zynlonta arm remained in CR vs 16.7% in the control arm. - **Safety / Toxicity (The "Catch")**: - Serious Adverse Events (SAEs) were 49.0% (Zynlonta+rituximab) vs 34.5% (R-GemOx). - Grade 5 (fatal) treatment-emergent adverse events (TEAEs) were three times higher in the Zynlonta+rituximab arm: **13.2% (27 patients)** vs **4.6% (9 patients)** in the R-GemOx arm. - The company noted that the majority of Grade 5 TEAEs in the test arm occurred in patients aged 75 years or older. - TEAEs leading to drug withdrawal were 25.5% vs 9.1%. - Specific toxicities higher in the test arm: infection/infestations (24.5% vs 15.7%), hepatotoxicity (17.2% vs 8.1%), and edema/effusion (7.4% vs 0.5%). - **Regulatory Implications**: Zynlonta is currently approved under FDA accelerated approval (third-line DLBCL), and LOTIS-5 is the confirmatory trial required to secure full approval and move into second-line treatment. The safety signal (especially the 13.2% death rate vs 4.6% control) sent the stock down 53% as investors fear the FDA may reject full approval or restrict the label significantly. - **Next Steps**: ADC Therapeutics plans a pre-sBLA meeting with the FDA in August 2026 and plans to submit the sBLA in Q4 2026. This is a very clear and substantial new drug-trial finding that fits the brief perfectly. I will write a detailed finding for it. Let's check if there is any other major science/health news. Let's search for "H5N1" or "avian influenza" or "bird flu" over the last week. Let's run a search.

Ah! "mRNA bird flu vaccine hits late-stage testing" in the Morning Medical Update (June 6, 2026). Let's search for "mRNA bird flu vaccine" or "Moderna" or "CSL Seqirus" H5N1 vaccine Phase 3 or late-stage testing in June 2026. Let's see: `mRNA bird flu vaccine hits late-stage testing`. Let's run a search for this specifically to see what is happening.

This is very interesting! Let's see: 1. "Moderna has begun a late-stage trial of its experimental bird flu vaccine, mRNA-1018, enrolling approximately 4,000 healthy adults in the United States and..." wait, let's fetch the Medical Economics article to see what it says exactly about the H5N1 vaccine and the clinical trial. 2. "Moderna receives up to $50 million from CEPI to develop a vaccine for the Bundibugyo ebolavirus as cases rise in the Democratic Republic of the Congo" (June 1, 2026). This is a direct update to the watch `019e99fb-4aa9-7dae-b1bb-e5b2ce833775` ("Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines")! Let's search for this CEPI funding to Moderna for Bundibugyo Ebola vaccine. First, let's fetch the Medical Economics article to read about the mRNA bird flu vaccine.

This is incredibly useful. Let's look at the details: 1. **Moderna's H5N1 mRNA vaccine (mRNA-1018)**: - It has entered Phase 3 late-stage clinical trials in the US and UK, enrolling approximately 4,000 healthy adults. - This is the first time an mRNA-based pandemic bird flu vaccine has reached Phase 3 trials. - The trial is backed by a $54 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI). - This funding from CEPI stepped in after HHS Secretary Robert F. Kennedy Jr. canceled more than $700 million in U.S. government contracts with Moderna for bird flu vaccine development last May. - Under the CEPI agreement, if approved and a flu pandemic is declared, Moderna will reserve 20% of its manufacturing capacity for supply to low- and middle-income countries (LMICs) at affordable prices. - Regulatory filings will also be supported by data from its seasonal flu candidate mRNA-1010, which is currently under review in the US, EU, Canada, and Australia. This is a major development in pandemic preparedness and public health policy! It represents a significant milestone in H5N1 vaccine development and reflects the current administration's policy shifts (HHS Secretary Robert F. Kennedy Jr. canceling the U.S. contracts, leading to CEPI stepping in). Let's also search for the other item: "Moderna receives up to $50 million from CEPI to develop a vaccine for the Bundibugyo ebolavirus as cases rise in the Democratic Republic of the Congo" (June 1, 2026). Let's search for this to find the exact details of the CEPI funding to Moderna for Bundibugyo. This directly addresses the watch on clinical trial initiation for fast-tracked Bundibugyo Ebola vaccines (`019e99fb-4aa9-7dae-b1bb-e5b2ce833775`). Let's run a search.

This is extremely exciting. Let's fetch the Reuters article: `https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-partners-with-global-health-coalition-develop-bundibugyo-ebola-vaccine-2026-06-01/` or the Ars Technica one to get exact figures and quotes, or let's read the CIDRAP article `https://www.cidrap.umn.edu/ebola/three-ebola-vaccine-candidates-fast-tracked-african-outbreak-continues` or `https://cepi.net/cepi-fast-tracks-three-bundibugyo-ebolavirus-vaccine-candidates`. Let's fetch the Reuters article first.

This is incredibly detailed! Let's examine the details of the fast-tracked Bundibugyo Ebola vaccines: - **CEPI Funding**: Just over $60 million total committed by CEPI to three vaccine developers on June 1, 2026: 1. **Moderna**: Up to $50 million to support preclinical and early clinical development of its mRNA-based investigational BDBV vaccine candidate. 2. **University of Oxford / Serum Institute of India (SII)**: Up to $8.6 million for their viral vector vaccine candidate, **ChAdOx1 Bundibugyo** (using the same technology as the Oxford/AstraZeneca COVID-19 vaccine). 3. **International AIDS Vaccine Initiative (IAVI)**: An initial $3.2 million for its single-dose BDBV candidate (using the same recombinant vesicular stomatitis virus [rVSV] technology as Merck's approved Zaire Ebola vaccine Ervebo). - **Target**: These candidates are aimed at the rare Bundibugyo ebolavirus strain, for which no approved vaccine or treatment currently exists. - **Context/Timeline**: CEPI's head Richard Hatchett stated it was possible to get these vaccines ready for clinical trials "within a couple of months." - **Additional Funding**: Separately, Gavi committed up to $50 million to the Ebola response, and the World Bank's Pandemic Fund announced up to $220.6 million in grants. This is a direct, substantial update to the prior finding `bundibugyo-ebola-outbreak-drc-uganda` and specifically triggers an update/event for the watch `019e99fb-4aa9-7dae-b1bb-e5b2ce833775` ("Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines"). The watch is ongoing, so we should keep it open, but we can record an event for it since CEPI has officially fast-tracked these three candidates with $60M in funding. Wait, the watch trigger is: "Fires when Phase 1 clinical trials for any of the three fast-tracked Bundibugyo Ebola vaccines begin enrolling or report initial safety/immunogenicity data." Does the June 1 announcement mean Phase 1 has begun enrolling? No, the Reuters article says "it was possible to get Ebola Bundibugyo (BDBV) vaccines ready for trials within a couple of months" and "tens of millions of dollars until we're in a position to enter the clinic." So Phase 1 has not yet begun enrolling. The watch has not fired, but we have a major update on the funding and preparation for these trials, which we should add to our findings note. Let's look for other potential stories. Are there other major clinical trials? Let's search for "ASCO 2026" or "FDA approval" or "Phase 3 clinical trial" or "breakthrough" in the last week. Let's run a search for "ASCO 2026" to see if there are any other late-breaking clinical trials that we should cover, or other drug approvals. We have `daraxonrasib-pancreatic-cancer-survival-doubled` and `ivonescimab-harmoni-6-lung-cancer-os-win`. Let's search for "ASCO 2026" to see what else happened.

Ah, the search budget is spent. That is perfectly fine, we have two incredibly strong and on-topic stories with deep primary source evidence that we fetched! Let's review the two stories we have: 1. **The Ebola Bundibugyo Outbreak (and the fast-tracked vaccines)**: - The outbreak is expanding, with cases rising to 488 in the DRC (86 deaths) and 19 in Uganda (2 deaths) as of June 6, 2026. - The WHO and Africa CDC unveiled a $518 million containment plan to run from June to November 2026. - A US surgeon, Dr. Peter Stafford (39), who was infected while operating in the DRC, recovered in quarantine at Berlin's Charité hospital after receiving experimental treatments and was discharged on June 6, 2026. - In Kenya, protests against a US-built Ebola quarantine facility at Laikipia Air Base turned violent, leaving at least two dead. - On June 1, 2026, CEPI committed just over $60 million to fast-track three investigational Bundibugyo Ebola vaccines: up to $50 million to Moderna (mRNA candidate), up to $8.6 million to the University of Oxford / Serum Institute of India (ChAdOx1 viral vector), and an initial $3.2 million to the International AIDS Vaccine Initiative (IAVI, rVSV candidate). - This directly refines and updates the prior finding `bundibugyo-ebola-outbreak-drc-uganda`. 2. **ADC Therapeutics' Zynlonta Phase 3 LOTIS-5 trial results**: - On June 3, 2026, ADC Therapeutics announced topline results from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). - The trial met its primary endpoint of progression-free survival (PFS) with statistical significance (median PFS 6.1 months vs 4.7 months, HR = 0.73, p = 0.008). - However, the stock crashed over 50% due to major safety concerns: there was a threefold increase in deaths (Grade 5 treatment-emergent adverse events) in the Zynlonta arm (13.2% or 27 patients) compared to the control arm (4.6% or 9 patients). - The majority of these fatal events occurred in patients aged 75 or older. Other toxicities such as hepatotoxicity and edema/effusion were also elevated in the Zynlonta arm. - Despite the safety signals, the company plans a pre-sBLA meeting with the FDA in August 2026, targeting an sBLA submission in Q4 2026. - This is a new finding (fresh slug: `zynlonta-phase3-lotis5-dlbcl-safety-concerns`). 3. **Moderna's H5N1 mRNA Influenza Vaccine (mRNA-1018)**: - On June 6, 2026, it was highlighted that Moderna's experimental H5N1 bird flu vaccine mRNA-1018 has entered a late-stage Phase 3 trial enrolling ~4,000 healthy adults in the US and UK. - This is the first mRNA-based pandemic bird flu vaccine to reach Phase 3. - The trial is funded by a $54 million investment from CEPI, which stepped in after HHS Secretary Robert F. Kennedy Jr. canceled more than $700 million in U.S. government contracts with Moderna for bird flu vaccine development in May 2025. - Under the CEPI agreement, Moderna will reserve 20% of its manufacturing capacity for supply to low- and middle-income countries (LMICs) during a declared pandemic. - This is a new finding (fresh slug: `moderna-h5n1-mrna-vaccine-phase3-cepi-funding`). Wait, is there any other prior finding we should check? Let's look at the prior findings: - `grail-nhs-galleri-mced-trial-results` - `bundibugyo-ebola-outbreak-drc-uganda` - `ivonescimab-harmoni-6-lung-cancer-os-win` - `salanersen-fda-breakthrough-spinal-muscular-atrophy` - `first-cat-to-human-h5n1-transmission` Yes, `bundibugyo-ebola-outbreak-drc-uganda` is directly updated. Let's write three notes: 1. Revise `bundibugyo-ebola-outbreak-drc-uganda` with the latest case counts, the $518m WHO plan, the recovery of Dr. Stafford, the Kenya protests, and the $60M CEPI vaccine fast-track. 2. Write a new note for `zynlonta-phase3-lotis5-dlbcl-safety-concerns` covering the LOTIS-5 PFS win but 3x death rate. 3. Write a new note for `moderna-h5n1-mrna-vaccine-phase3-cepi-funding` covering the Phase 3 launch of the first mRNA bird flu vaccine, the RFK Jr. contract cancelation background, and CEPI's $54M backup funding. Let's write the first note. Wait, let's draft the first note body. Rule check: - Title is the first `# ` heading. - No YAML frontmatter. - Every note must carry 1-2 representative verbatim quotes, each kept with the link it came from. - Slug is lowercase, hyphens, and passed as parameter. - Use wikilinks `[[slug]]` to refer to other findings if needed. Let's write the updated Ebola note. We will use the slug `bundibugyo-ebola-outbreak-drc-uganda`. Let's see what the previous note preview was: "The severe outbreak of Ebola caused by the rare Bundibugyo ebolavirus strain has entered a highly critical phase, prompting dire warnings from the U.S. Centers for Disease Control and Prevention..." Let's write a comprehensive update. Let's write the first note: `bundibugyo-ebola-outbreak-drc-uganda`.

Now let's write the second note for the Zynlonta Phase 3 LOTIS-5 trial results. The slug will be `zynlonta-phase3-lotis5-dlbcl-safety-concerns`. Let's draft the body. No YAML frontmatter, title is first heading, 1-2 verbatim quotes with links, external sources in Sources block. Let's write the note.

Excellent. Now let's write the third note for Moderna's H5N1 mRNA Influenza Vaccine (mRNA-1018). The slug will be `moderna-h5n1-mrna-vaccine-phase3-cepi-funding`. Let's draft the body. No YAML frontmatter, title is first heading, 1-2 verbatim quotes with links, external sources in Sources block. Let's write the note.

Awesome. Now let's review the watches and see if we should register any new watches or resolve any existing threads. Let's see what threads are currently open: - `019e99fc-06fa-7337-8d0d-d4d884b4ceb2` (watch, ongoing): "NHS-Galleri trial cancer mortality data release" -> not fired. - `019e99fb-cefe-7c1d-a08f-e848720ecf10` (watch, one_shot, fire_date 2027-02-01): "NMPA regulatory decision on IBI343" -> not fired. - `019e99fb-8b38-7220-afca-dbbf935aa64e` (watch, ongoing): "Global Phase 3 trial readouts for ivonescimab (HARMONi studies)" -> not fired. - `019e99fb-4aa9-7dae-b1bb-e5b2ce833775` (watch, ongoing): "Clinical trial initiation/readout for fast-tracked Bundibugyo Ebola vaccines" -> not fired, but we have a massive update on the vaccine development (CEPI's $60M funding to Moderna, Oxford, and IAVI on June 1, 2026). Let's record an event for this watch but keep it open (resolves: false). Let's record the event on the Bundibugyo Ebola vaccine watch: Thread ID: `019e99fb-4aa9-7dae-b1bb-e5b2ce833775` Cycle ID: `d14cc7c3-3cf9-41e4-b807-9b63b9f7ec48` Summary: CEPI fast-tracks three Bundibugyo Ebola vaccine candidates with $60M in funding. Resolves: `false` (it's an ongoing watch, and Phase 1 clinical trial enrollment hasn't officially started yet). Let's do that.

This is great. Now let's check if we should set up any new watches. For Zynlonta: - We have the upcoming pre-sBLA meeting in August 2026 and the planned sBLA submission in Q4 2026. This is a very clear forward-looking event that we should watch for. Let's register a watch for this: - `watch_type`: `live_process` or `dated_catalyst` (since we know the target dates: August 2026 and Q4 2026). Let's use `live_process` or `dated_catalyst`. Let's use `dated_catalyst` with a target date around late 2026. Let's make it `one_shot`. - Title: "sBLA submission for Zynlonta plus rituximab in r/r DLBCL" - Description: "Monitor ADC Therapeutics' planned sBLA submission in Q4 2026 and the pre-sBLA meeting in August 2026 to see if safety concerns (13.2% death rate) affect the timeline or regulatory path." - Entity: "ADC Therapeutics / FDA" - Fire date: "2026-12-31T00:00:00Z" Let's register this watch.

Let's register another watch for the Moderna H5N1 vaccine: - Title: "Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout" - Description: "Monitor topline safety and immunogenicity data from Moderna's Phase 3 trial of mRNA-1018 in the US and UK." - Entity: "Moderna" - Cardinality: "one_shot" - Watch type: "live_process" Let's register this watch.

This is excellent. We have written three high-quality notes: 1. `bundibugyo-ebola-outbreak-drc-uganda` (refining and updating a prior finding) 2. `zynlonta-phase3-lotis5-dlbcl-safety-concerns` (a new finding) 3. `moderna-h5n1-mrna-vaccine-phase3-cepi-funding` (a new finding) We have also registered two new watches: 1. sBLA submission for Zynlonta plus rituximab in r/r DLBCL (dated_catalyst, one_shot) 2. Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout (live_process, one_shot) And we recorded an event on the existing ongoing watch for the Bundibugyo Ebola vaccine development (`019e99fb-4aa9-7dae-b1bb-e5b2ce833775`). Let's complete the cycle by calling `finish_cycle`. Since we wrote findings, we do not need to pass `no_findings_reason`. Let's do that.

I have successfully completed this research cycle on consequential science and health. Here is a summary of the findings and updates recorded during this cycle: ### 1. Major Update to the Bundibugyo Ebola Outbreak in DRC and Uganda * **Finding Refined:** [[bundibugyo-ebola-outbreak-drc-uganda]] * **Developments:** * **Surging Cases:** As of June 6, 2026, cases in the DRC have climbed to 488 (with 86 deaths), while Uganda has confirmed 19 cases and two deaths. The US CDC warned that the outbreak could swell to over 20,000 cases, rivalling the 2014–2016 West Africa epidemic if not contained. * **Emergency Response:** The WHO and Africa CDC unveiled a $518 million containment plan running from June to November 2026. * **Vaccine Fast-Tracking:** On June 1, 2026, CEPI committed just over $60 million to fast-track three investigational Bundibugyo Ebola vaccines: **Moderna** (up to $50M for an mRNA candidate), **University of Oxford / Serum Institute of India** (up to $8.6M for viral vector ChAdOx1), and **IAVI** (initial $3.2M for rVSV). * **Clinical & Geopolitical Events:** Dr. Peter Stafford, a 39-year-old US surgeon infected while operating in the DRC, recovered in quarantine at Berlin's Charité hospital and was discharged on June 6. Meanwhile, violent protests in Kenya against a US-built Ebola quarantine facility near Laikipia Air Base resulted in at least two deaths. * **Watch Event Recorded:** Recorded a milestone event under the ongoing watch for the fast-tracked Bundibugyo Ebola vaccines (`019e99fb-4aa9-7dae-b1bb-e5b2ce833775`). ### 2. Zynlonta Phase 3 LOTIS-5 Trial Safety Concerns * **New Finding:** [[zynlonta-phase3-lotis5-dlbcl-safety-concerns]] * **Developments:** On June 3, 2026, ADC Therapeutics announced that its Phase 3 LOTIS-5 confirmatory trial of Zynlonta (loncastuximab tesirine-lpyl) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) met its primary endpoint of progression-free survival (median PFS 6.1 months vs 4.7 months, HR = 0.73, p = 0.008) and demonstrated high complete response rates. * **The Catch:** Despite the PFS win, the company's stock crashed over 50% due to a severe safety signal: a three-fold increase in fatal (Grade 5) treatment-emergent adverse events in the Zynlonta arm compared to the control arm (**13.2% / 27 patients** vs **4.6% / 9 patients**). The majority of these deaths occurred in patients aged 75 or older. Other toxicities such as hepatotoxicity and edema/effusion were also elevated. * **Regulatory Watch Registered:** Registered a one-shot watch (`019e9f1e-b37e-771d-884b-b07383d792b7`) to monitor the planned pre-sBLA FDA meeting in August 2026 and subsequent sBLA submission in Q4 2026 to see how the safety data impacts approval. ### 3. First mRNA-Based H5N1 Bird Flu Vaccine Phase 3 Launch * **New Finding:** [[moderna-h5n1-mrna-vaccine-phase3-cepi-funding]] * **Developments:** Moderna has launched a late-stage Phase 3 clinical trial of its experimental pandemic influenza vaccine, **mRNA-1018**, enrolling approximately 4,000 healthy adults in the US and UK. This is the first mRNA-based bird flu vaccine to reach Phase 3. * **Funding Shift:** The trial is backed by a $54 million investment from CEPI, which stepped in after HHS Secretary Robert F. Kennedy Jr. canceled more than $700 million in U.S. government contracts with Moderna for bird flu vaccine development in May 2025. In exchange for the funding, Moderna committed to reserving 20% of its vaccine manufacturing capacity for low- and middle-income countries (LMICs) during a declared pandemic. * **Watch Registered:** Registered a one-shot watch (`019e9f1e-f092-7114-960b-1c3b5c994320`) to monitor the eventual topline safety and immunogenicity trial readouts.